BPDCN International Registry shared a post on LinkedIn:
“New data from the BPDCN International Registry (NCT05430971) shed light on the role of allogeneic hematopoietic stem cell transplantation in BPDCN.
Among 70 patients enrolled across 17 centers worldwide, 16 underwent allo-HCT. At a median follow-up of 27 months, 63% of transplanted patients were alive. Most received ALL-based induction prior to transplant, and the majority proceeded to allo-HCT in first remission.
The data reinforce an important message: in eligible patients with BPDCN, optimizing access to tagraxofusp followed by allo-HCT may offer the best potential to improve long-term outcomes.
In a disease as rare and aggressive as BPDCN, every data point matters. Multicenter registries make it possible to generate real-world evidence that single institutions simply cannot produce alone.
The registry continues to grow. Centers managing BPDCN cases are warmly welcome to join this international collaborative effort.”
Title: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) international registry: Assessment of the allo-HCT outcomes
Authors: Lusine Harutyunyan, Marina Konopleva, Maria Badikyan, Alvaro Alencar, Arusyak Ivanyan, Carolyn Owen, Ching-Tien Peng, Dickran Kazandjian, Funda Tekkesin, Justin Taylor, Hasanein Ghali, Hasmik Maghaqyan, Karen Bedirian, Maria Paola Martelli, Enrico Attardi, Maria Teresa Voso, Mariam Abramashvili, Mazin Faisal Al-Jadiry, Michalis Michael, Min-Yu Su, Daniel Coriu, Maria Camelia Stancioaica, Hayk Grigoryan, Nerses Ghahramanyan, Nare Martirosyan, Nino Totogashvili, Pavel Kotoucek, Rejin Kebudi, Robin Ohannessian, Ruzanna Papyan, Shushan Hovsepyan, Shefali Mehra, Salma Elashwah, Sameer Bakhshi, Samvel Bardakhchyan, Shaimaa El-Ashwah, Tezer Kutluk, Deniz Tuğcu, Ahmad Alhuraiji, Naveen Pemmaraju, Rami Komrokji, Gevorg Tamamyan, Astghik Voskanyan
Other articles from BPDCN International Registry on LinkedIn.